



TEL:4006-871-227 Web:www.ybio.net Email:shybio@126.com

YB91989Hu01
Toll Like Receptor 3 (TLR3)
Organism: Homo sapiens (Human)
Instruction manual

FOR IN VITRO USE AND RESEARCH USE ONLY
NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES

4th Edition (Revised in August, 2012)

[DESCRIPTION]

Protein Names: Toll Like Receptor 3

Synonyms: TLR3

Species: Human

Size: 100µg

Source: *Escherichia coli*-derived

Subcellular Location: Endoplasmic reticulum membrane; Single-pass type I membrane protein. Endosome membrane.

[PROPERTIES]

Residues: Leu404~Leu532 (Accession # O15455), with two N-terminal Tags, His-tag and S-tag.

Grade & Purity: >95%, 20 kDa as determined by SDS-PAGE reducing conditions.

Formulation: Supplied as liquid form in Phosphate buffered saline(PBS), pH 7.4.

Endotoxin Level: <1.0 EU per 1µg (determined by the LAL method).

Applications: SDS-PAGE; WB; ELISA; IP.

(May be suitable for use in other assays to be determined by the end user.)

Predicted Molecular Mass: 20.44 kDa

Predicted isoelectric point: 5.6

[PREPARATION]

Reconstitute in sterile PBS, pH7.2-pH7.4.



TEL:4006-871-227 Web:www.ybio.net Email:shybio@126.com

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months .

Stability Test: The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.

[SEQUENCES]

The target protein is fused with two N-terminal Tags, His-tag and S-tag, its sequence is listed below.

MHHHHHSSG LVPRGSGMKE TAAAKFERQH MDSPDLGTDD DDKAMADIGS EF-LAHSPLHI LNLTKNKISK IESDAFSWLG
HLEVLDLGLN EIGQELTGQE WRGLENIFEI YLSYNKYQLL TRNSFALVPS LQRLMLRRVA LKNVDSSPSP FQPLRNLTIL
DLSNNNIANI NDDMLEGLEK L

[REFERENCES]

1. Rock F.L., *et al.* (1998) Proc. Natl. Acad. Sci. U.S.A. 95:588-593.
2. Lafon M., *et al.* (2006) J. Mol. Neurosci. 29:185-194.
3. Nakajima T., *et al.* (2008) Immunogenetics 60:727-735.
4. The MGC Project Team. (2004) Genome Res. 14:2121-2127.